Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2012

01-12-2012 | Interstitial Lung Disease (G Tino, Section Editor)

Non-pharmacological treatment of idiopathic pulmonary fibrosis

Authors: Huzaifa I. Adamali, Muhammad S. Anwar, Anne-Marie Russell, Jim J. Egan

Published in: Current Pulmonology Reports | Issue 4/2012

Login to get access

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fatal disorder that remains difficult to treat. In this review, we examine non-pharmacological treatment modalities, including lung transplantation, pulmonary rehabilitation and palliation. Lung transplantation, the only therapeutic intervention that offers survival benefit, should be considered in all IPF patients with progressive disease who meet the International Society for Heart and Lung transplantation guidelines. Pulmonary rehabilitation improves exercise capacity, reduces dyspnoea and improves quality of life in IPF patients, and should be made available to patients. For those patients with advanced disease, palliative services offer symptom management, improved quality of life and psychological support for patients and their caregivers.
Literature
1.
•• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. Reference guidelines for the management of IPF. PubMedCrossRef
2.
•• Adamali HI, Maher TM. A review of current and novel therapies for Idiopathic Pulmonary Fibrosis. Drug Des Devel Ther. 2012 (in press) Comprehensive review on pirfenidone and promising upcoming therapies.
3.
4.
•• Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart–Lung Transplant Report—2011. J Heart Lung Transplant. 2011;30:1123–32. Excellent resource to show trends for all diagnostic groups that underwent transplantation. PubMedCrossRef
5.
Osaki S, Maloney JD, Meyer KC, et al. The impact of the lung allocation scoring system at the single national Veterans Affairs Hospital lung transplantation program. Eur J Cardiothorac Surg. 2009;36:497–501.PubMedCrossRef
6.
Meyers BF, Lynch JP, Battafarano RJ, et al. Lung transplantation is warranted for stable, ventilator-dependent recipients. Ann Thorac Surg. 2000;70:1675–8.PubMedCrossRef
7.
• Weiss ES, Allen JG, Merlo CA, et al. Lung allocation score predicts survival in lung transplantation patients with pulmonary fibrosis. Ann Thorac Surg. 2009;88:1757–64. Excellent paper looking at the role of LAS. PubMedCrossRef
8.
•• Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–55. A very good resource. PubMedCrossRef
9.
Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. J Heart Lung Transplant. 2007;26:782–95.PubMedCrossRef
10.
Enomoto N, Suda T, Kato M, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006;130:22–9.PubMedCrossRef
11.
Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;15(166):173–7.CrossRef
12.
Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol. 2000;24:19–33.PubMedCrossRef
13.
Tafti SF, Mokri B, Mohammadi F, et al. Comparison of clinicoradiologic manifestation of nonspecific interstitial pneumonia and usual interstitial pneumonia/idiopathic pulmonary fibrosis: A report from NRITLD. Ann Thorac Med. 2008;3:140–5.PubMedCrossRef
14.
Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172:488–93.PubMedCrossRef
15.
Screaton NJ, Hiorns MP, Lee KS, et al. Serial high resolution CT in non-specific interstitial pneumonia: prognostic value of the initial pattern. Clin Radiol. 2005;60:96–104.PubMedCrossRef
16.
Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58:143–8.PubMedCrossRef
17.
Martinez FJ. Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia. Proc Am Thorac Soc. 2006;3:81–95.PubMedCrossRef
18.
Mogulkoc N, Brutsche M, Bishop P, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001;164:103–8.PubMed
19.
Lynch D, Godwin J, Safrin S, Idiopathic Pulmonary Fibrosis Study Group, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172:488–93.PubMedCrossRef
20.
Jegal U, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639–44.PubMedCrossRef
21.
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–7.PubMedCrossRef
22.
Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005;60:270–3.PubMedCrossRef
23.
• Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63 Suppl 5:v1–v58. Good resource for guidelines. New ones are awaited this year. PubMed
24.
Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.PubMedCrossRef
25.
Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:402–7.PubMedCrossRef
26.
Lama V, Flaherty K, Toews G, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–90.PubMedCrossRef
27.
Kawut SM, O’Shea MK, Bartels MN, et al. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med. 2005;99:1431–9.PubMedCrossRef
28.
Swigris J, Swick J, Wamboldt F, et al. Heart Rate Recovery After 6-Minute Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2009;136:814–8.CrossRef
29.
Nadrous H, Pellikka P, Krowka M, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128:2393–9.PubMedCrossRef
30.
Patel N, Lederer D, Borczuk A, Kawut S. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132:998–1006.PubMedCrossRef
31.
Shorr A, Wainright J, Cors C, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30:715–21.PubMedCrossRef
32.
Nathan S, Shlobin O, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008;76:288–94.PubMedCrossRef
33.
Lettieri C, Nathan S, Barnett S, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–52.PubMedCrossRef
34.
Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:650–6.PubMedCrossRef
35.
Whelan T, Dunitz J, Kelly R, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005;24:1269–74.PubMedCrossRef
36.
• Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40:93–100. Establishes pulmonary hypertension in IPF predisposes patients to acute exacerbations and decrease survival. PubMedCrossRef
37.
Culver DA, Mazzone PJ, Khandwala F, et al. Discordant utility of ideal body weight and body mass index as predictors of mortality in lung transplant recipients. J Heart Lung Transplant. 2005;24:137–44.PubMedCrossRef
38.
Madill J, Gutierrez C, Grossman J, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant. 2001;20:288–96.PubMedCrossRef
39.
Seoane L, Arcement LM, Valentine VG, et al. Long-term survival in lung transplant recipients after successful preoperative coronary revascularization. J Thorac Cardiovasc Surg. 2005;130:538–41.PubMedCrossRef
40.
Lee R, Meyers BF, Sundt TM, et al. Concomitant coronary artery revascularization to allow successful lung transplantation in selected patients with coronary artery disease. J Thorac Cardiovasc Surg. 2002;124:1250–1.PubMedCrossRef
41.
• Nathan SD, Shlobin OA, Ahmad S, et al. Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J Heart Lung Transplant. 2010;29:1165–71. Excellent comparison of BLT and SLT in IPF. PubMedCrossRef
42.
Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg. 2005;79:950–7.PubMedCrossRef
43.
Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med. 2009;151:767–74.PubMed
44.
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic lung disease: a clinical trial. Ann Intern Med. 1980;93:391–8.
45.
Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1:681–6.
46.
• Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax. 2011;66 Suppl 1:i1-30. Excellent guidelines for managing respiratory patients who want to fly.
47.
Nici L, Donner C, ZuWallack R, et al. American Thoracic Society and the European Respiratory Society statement on pulmonary rehabilitation. Am J Resp Crit Care Med. 2006;173:1390–413.PubMedCrossRef
48.
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007;131:4–42S.CrossRef
49.
Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–9.PubMedCrossRef
50.
Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549–54.PubMedCrossRef
51.
• Kozu R, Senjyu H, Jenkins S, et al. Differences in Response to Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease. Respiration. 2011;81:196–205. First prospective controlled trail to compare the benefit of PR in IPF and COPD. PubMedCrossRef
52.
• Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest. 2010;137:273–9. This paper showed sustained improvement in ILD. PubMedCrossRef
53.
• Holland AE. Exercise limitation in interstitial lung disease: mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7:101–11. Very interesting data to look at different mechanisms of exercise limitations. PubMedCrossRef
54.
Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest. 2005;127:2028–33.PubMedCrossRef
55.
Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Systematic Review. 2010;7(7):CD006704.
56.
• Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis. Respir Care. 2011;56(6):783–9. A 6 week pilot study showing improvements in functional capacity and fatigue. PubMedCrossRef
57.
Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135:442–7. The most robust trial to look at the predictors of benefit in IPF. PubMedCrossRef
58.
Holland AE, Hill C, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012;106(3):429–35.PubMedCrossRef
59.
• Kozu R, Jenkins S, Senjyu H, et al. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respiration. 2011;16:1196–202. Establishes that patients with less symptomatic disease benefit from PR..
60.
61.
Thomas K. Caring for the dying at home-Companions on the journey. Oxford: Radcliffe Medical Press; 2003.
62.
63.
64.
65.
Stern JB, Mal H, Groussard O, et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001;120:213–9.PubMedCrossRef
66.
Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest. 2001;120:209–12.PubMedCrossRef
67.
Saydain G, Islam A, Afessa B, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med. 2002;166:839–42.PubMedCrossRef
68.
De Vries J, Kessels BLJ, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J. 2001;17:954–61.PubMedCrossRef
69.
Hope-Gill BDM, Hilldrup S, Davies C. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care. 2003;168:995–1002.CrossRef
70.
• Yorke J, Jones PW, Swigris JJ. Development & Validity Testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax. 2010;65:921–6. Adaptation of a HRQoL tool for specific use in IPF patients. PubMedCrossRef
71.
Mahler D, Weinberg D, Wells C, Feinstein A. The measurement of dyspnoea: contents, inter-observer agreement and physiological correlates of two clinical indexes. Chest. 1984;85:751–8.PubMedCrossRef
72.
• Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36:1067-72. Establishes the MRC Dyspnoea score as a robust tool. PubMedCrossRef
73.
• Key AL, Holt K, Hamilton A, et al. Objective Cough Frequency in Idiopathic Pulmonary Fibrosis. Cough. 2010;6:4. A good paper that establishes cough as a distressing symptom and patients perception of cough frequency as accurate. PubMedCrossRef
74.
Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19:128–30.PubMedCrossRef
75.
Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax. 2008;63:749.PubMedCrossRef
76.
• Horton MR, Santopeitro V, Matthew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med. 2012;157:398–406. A promising therapy for a troublesome symptom that is being put through the rigors of clinical trial.
77.
Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: A systematic review. Respir Med. 2007;101:399–410.PubMedCrossRef
78.
Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat Med. 2001;15:287–95.PubMedCrossRef
Metadata
Title
Non-pharmacological treatment of idiopathic pulmonary fibrosis
Authors
Huzaifa I. Adamali
Muhammad S. Anwar
Anne-Marie Russell
Jim J. Egan
Publication date
01-12-2012
Publisher
Current Science Inc.
Published in
Current Pulmonology Reports / Issue 4/2012
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-012-0031-z

Other articles of this Issue 4/2012

Current Pulmonology Reports 4/2012 Go to the issue

Asthma (S Peters and J Oppenheimer, Section Editors)

The Childhood Asthma Management Program (CAMP): contributions to the understanding of therapy and the natural history of childhood asthma

Interstitial Lung Disease (G Tino, Section Editor)

Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications

Asthma (S Peters and J Oppenheimer, Section Editors)

Asthma clinical trials of American Lung Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12 years?

Interstitial Lung Disease (G Tino, Section Editor)

Diagnostic approach to interstitial lung disease

Interstitial Lung Disease (G Tino, Section Editor)

Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going

Asthma (S Peters and J Oppenheimer, Section Editors)

Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits